|
|
||||||||
Papers In Press, published online ahead of print April 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Dept. II, Grosshadern, Munich 81377
Corresponding Author: parhofer{at}med2.med.uni-muenchen.de
Postprandial lipoprotein metabolism is impaired in hypertriglyceridemia. It is unknown how and to what extent atorvastatin affects postprandial lipoprotein metabolism in hypertriglyceridemic patients. We evaluated the effect of 4 weeks of atorvastatin therapy (10mg/day) on postprandial lipoprotein metabolism in 10 hypertriglyceridemic patients (age 40±3years, BMI 27±1kg/m2, cholesterol 5.74±0.34, triglyceride 3.90±0.66, HDL-cholesterol 0.85±0.05, LDL-cholesterol 3.18±0.23mmol/L). Patients were randomized to be studied either first with or without atorvastatin therapy. Postprandial lipoprotein metabolism was evaluated with a standardized oral fat load. Plasma was obtained every 2h for 14h. Large triglyceride-rich lipoproteins (TRL) (containing chylomicrons) and small TRL (containing chylomicron-remnants) were isolated by ultracentrifugation and cholesterol, triglyceride, apoB-100, apoB-48, apoC-III and retinyl-palmitate concentrations were determined. Atorvastatin significantly (p<0.01) decreased fasting cholesterol (-27%), triglyceride (-43%), LDL-cholesterol (-28%), and apoB-100 (-31%) and increased HDL-cholesterol (+19%). Incremental area under the curve (AUC) significantly (p<0.05) decreased for large TRL-cholesterol, -triglyceride, and -retinyl-palmitate, while none of the small TRL parameters changed. These findings contrast with the results in normolipidemic subjects where atorvastatin decreased AUC for chylomicron remnants (small TRL) but not for chylomicrons (large TRL). We conclude that atorvastatin improves postprandial lipoprotein metabolism in addition to decreasing fasting lipid levels in hypertriglyceridemia. Such changes would be expected to improve the atherogenic profile.
Revised on March 25, 2003
Accepted on March 25, 2003
Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism J. Lipid Res., August 1, 2007; 48(8): 1746 - 1753. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vidal, S. Hernandez-Vallejo, T. Pauquai, O. Texier, M. Rousset, J. Chambaz, S. Demignot, and J.-M. Lacorte Apple procyanidins decrease cholesterol esterification and lipoprotein secretion in Caco-2/TC7 enterocytes J. Lipid Res., February 1, 2005; 46(2): 258 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Chung, B. S. Cho, P. Liang, S. Doran, L. Osterlund, R. A Oster, B. Darnell, and F. Franklin Contribution of postprandial lipemia to the dietary fat-mediated changes in endogenous lipoprotein-cholesterol concentrations in humans Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1145 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Verseyden, S. Meijssen, and M. C. Cabezas Effects of Atorvastatin on Fasting Plasma and Marginated Apolipoproteins B48 and B100 in Large, Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5021 - 5029. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |